Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of April 16, 2025, REGENXBIO (RGNX) has a market cap of $0.33 billion USD. According to our data, REGENXBIO is ranked No.6422 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Apr 16, 2025 | $0.33 B |
-14.29%
|
| Dec 31, 2024 | $0.38 B |
-56.94%
|
| Dec 29, 2023 | $0.89 B |
-20.86%
|
| Dec 30, 2022 | $1.12 B |
-30.64%
|
| Dec 31, 2021 | $1.62 B |
-27.91%
|
| Dec 31, 2020 | $2.25 B |
10.72%
|
| Dec 31, 2019 | $2.03 B |
-2.34%
|
| Dec 31, 2018 | $2.08 B |
26.17%
|
| Dec 29, 2017 | $1.65 B |
79.25%
|
| Dec 30, 2016 | $0.92 B |
11.75%
|
| Dec 31, 2015 | $0.82 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 bluebird bio
BLUE
|
$43.76 M |
0.000 M
|
USA
|
 Boundless Bio
BOLD
|
$30.11 M |
0.000 M
|
USA
|
 Sangamo Therapeutics
SGMO
|
$0.17 B |
0.000 M
|
USA
|
 REGENXBIO
RGNX
|
$0.33 B |
-0.000 M
|
USA
|
 Ionis Pharmaceuticals
IONS
|
$4.51 B |
0.000 M
|
USA
|
 CRISPR Therapeutics
CRSP
|
$3.34 B |
0.000 M
|
Switzerland
|
 Editas Medicine
EDIT
|
$0.11 B |
0.000 M
|
USA
|
 Intellia Therapeutics
NTLA
|
$0.76 B |
-0.000 M
|
USA
|
 Novartis
NVS
|
$217.12 B |
0.003 M
|
Switzerland
|
 Biogen
BIIB
|
$17.12 B |
0.000 M
|
USA
|
 Gilead Sciences
GILD
|
$131.74 B |
-0.002 M
|
USA
|
 Amgen
AMGN
|
$158.77 B |
0.132 B
|
USA
|
 AbbVie
ABBV
|
$312.76 B |
-0.013 M
|
USA
|
| Market Cap | = | RGNX Stock Price | * | RGNX Shares Outstanding |
| = | $6.55 | * | 50.12 M | |
| = | $0.33 B |